Behandeling van patiënten met niet-kleincellig longcarcinoom stadium III: Gelijktijdig hooggedoseerde chemotherapie en radiotherapie

S. Y. El Sharouni; J. G.J.V. Aerts; S. Senan; D. K.M. De Ruysscher; H. J.M. Groen; M. A. Paul; E. F. Smit; E. J.A. Vonk; A. F. Verhagen; F. M.N.H. Schramel

Behandeling van patiënten met niet-kleincellig longcarcinoom stadium III: Gelijktijdig hooggedoseerde chemotherapie en radiotherapie

Translated title of the contribution: Treatment of patients with stage III non-small cell lung cancer: Concurrent high-dose chemotherapy and radiotherapy

S. Y. El Sharouni, J. G.J.V. Aerts, S. Senan, D. K.M. De Ruysscher, H. J.M. Groen, M. A. Paul, E. F. Smit, E. J.A. Vonk, A. F. Verhagen, F. M.N.H. Schramel

Research output: Contribution to journal › Review article › Academic › peer-review

Abstract

- The treatment of patients with locally advanced non-small cell lung cancer (stage III) has changed significantly in the past few years. - Patients with a non-resectable stage IIIA/B tumour are given combined treatment consisting of chemotherapy and radiotherapy. These can be administered sequentially or concurrently. - It has been shown recently that concurrent chemoradiotherapy gives a survival advantage in comparison with sequential chemoradiotherapy. - Cisplatin and etoposide are usually the drugs of choice for chemotherapy in patients with stage III cancer. - A biologically effective dose of radiotherapy equivalent to 60-66 Gy, over a maximum of 6.5 weeks, should be given. - Surgery is possible for a selected group of patients, provided a complete objective mediastinal response has been achieved after chemoradiotherapy and a complete resection appears to be technically feasible. It is recommended to apply this treatment in a research setting. - High-dose concurrent chemoradiotherapy is advised as the standard treatment for stage III non-small cell lung cancer in patients in good physical condition.

Translated title of the contribution	Treatment of patients with stage III non-small cell lung cancer: Concurrent high-dose chemotherapy and radiotherapy
Original language	Dutch
Pages (from-to)	2714-2717
Number of pages	4
Journal	Nederlands Tijdschrift voor Geneeskunde
Volume	152
Issue number	50
Publication status	Published - 13 Dec 2008

Access to Document

Link to publication in Scopus

Cite this

El Sharouni, S. Y., Aerts, J. G. J. V., Senan, S., De Ruysscher, D. K. M., Groen, H. J. M., Paul, M. A., Smit, E. F., Vonk, E. J. A., Verhagen, A. F., & Schramel, F. M. N. H. (2008). Behandeling van patiënten met niet-kleincellig longcarcinoom stadium III: Gelijktijdig hooggedoseerde chemotherapie en radiotherapie. Nederlands Tijdschrift voor Geneeskunde, 152(50), 2714-2717.

El Sharouni, S. Y. ; Aerts, J. G.J.V. ; Senan, S. ; De Ruysscher, D. K.M. ; Groen, H. J.M. ; Paul, M. A. ; Smit, E. F. ; Vonk, E. J.A. ; Verhagen, A. F. ; Schramel, F. M.N.H. / Behandeling van patiënten met niet-kleincellig longcarcinoom stadium III : Gelijktijdig hooggedoseerde chemotherapie en radiotherapie. In: Nederlands Tijdschrift voor Geneeskunde. 2008 ; Vol. 152, No. 50. pp. 2714-2717.

@article{cd13a6880c8c4de4af1c86331bd75ddb,

title = "Behandeling van pati{\"e}nten met niet-kleincellig longcarcinoom stadium III: Gelijktijdig hooggedoseerde chemotherapie en radiotherapie",

abstract = "- The treatment of patients with locally advanced non-small cell lung cancer (stage III) has changed significantly in the past few years. - Patients with a non-resectable stage IIIA/B tumour are given combined treatment consisting of chemotherapy and radiotherapy. These can be administered sequentially or concurrently. - It has been shown recently that concurrent chemoradiotherapy gives a survival advantage in comparison with sequential chemoradiotherapy. - Cisplatin and etoposide are usually the drugs of choice for chemotherapy in patients with stage III cancer. - A biologically effective dose of radiotherapy equivalent to 60-66 Gy, over a maximum of 6.5 weeks, should be given. - Surgery is possible for a selected group of patients, provided a complete objective mediastinal response has been achieved after chemoradiotherapy and a complete resection appears to be technically feasible. It is recommended to apply this treatment in a research setting. - High-dose concurrent chemoradiotherapy is advised as the standard treatment for stage III non-small cell lung cancer in patients in good physical condition.",

author = "{El Sharouni}, {S. Y.} and Aerts, {J. G.J.V.} and S. Senan and {De Ruysscher}, {D. K.M.} and Groen, {H. J.M.} and Paul, {M. A.} and Smit, {E. F.} and Vonk, {E. J.A.} and Verhagen, {A. F.} and Schramel, {F. M.N.H.}",

year = "2008",

month = dec,

day = "13",

language = "Dutch",

volume = "152",

pages = "2714--2717",

journal = "Nederlands Tijdschrift voor Geneeskunde",

issn = "0028-2162",

publisher = "Bohn Stafleu van Loghum",

number = "50",

}

Behandeling van patiënten met niet-kleincellig longcarcinoom stadium III : Gelijktijdig hooggedoseerde chemotherapie en radiotherapie. / El Sharouni, S. Y.; Aerts, J. G.J.V.; Senan, S.; De Ruysscher, D. K.M.; Groen, H. J.M.; Paul, M. A.; Smit, E. F.; Vonk, E. J.A.; Verhagen, A. F.; Schramel, F. M.N.H.

In: Nederlands Tijdschrift voor Geneeskunde, Vol. 152, No. 50, 13.12.2008, p. 2714-2717.

Research output: Contribution to journal › Review article › Academic › peer-review

TY - JOUR

T1 - Behandeling van patiënten met niet-kleincellig longcarcinoom stadium III

T2 - Gelijktijdig hooggedoseerde chemotherapie en radiotherapie

AU - El Sharouni, S. Y.

AU - Aerts, J. G.J.V.

AU - Senan, S.

AU - De Ruysscher, D. K.M.

AU - Groen, H. J.M.

AU - Paul, M. A.

AU - Smit, E. F.

AU - Vonk, E. J.A.

AU - Verhagen, A. F.

AU - Schramel, F. M.N.H.

PY - 2008/12/13

Y1 - 2008/12/13

N2 - - The treatment of patients with locally advanced non-small cell lung cancer (stage III) has changed significantly in the past few years. - Patients with a non-resectable stage IIIA/B tumour are given combined treatment consisting of chemotherapy and radiotherapy. These can be administered sequentially or concurrently. - It has been shown recently that concurrent chemoradiotherapy gives a survival advantage in comparison with sequential chemoradiotherapy. - Cisplatin and etoposide are usually the drugs of choice for chemotherapy in patients with stage III cancer. - A biologically effective dose of radiotherapy equivalent to 60-66 Gy, over a maximum of 6.5 weeks, should be given. - Surgery is possible for a selected group of patients, provided a complete objective mediastinal response has been achieved after chemoradiotherapy and a complete resection appears to be technically feasible. It is recommended to apply this treatment in a research setting. - High-dose concurrent chemoradiotherapy is advised as the standard treatment for stage III non-small cell lung cancer in patients in good physical condition.

AB - - The treatment of patients with locally advanced non-small cell lung cancer (stage III) has changed significantly in the past few years. - Patients with a non-resectable stage IIIA/B tumour are given combined treatment consisting of chemotherapy and radiotherapy. These can be administered sequentially or concurrently. - It has been shown recently that concurrent chemoradiotherapy gives a survival advantage in comparison with sequential chemoradiotherapy. - Cisplatin and etoposide are usually the drugs of choice for chemotherapy in patients with stage III cancer. - A biologically effective dose of radiotherapy equivalent to 60-66 Gy, over a maximum of 6.5 weeks, should be given. - Surgery is possible for a selected group of patients, provided a complete objective mediastinal response has been achieved after chemoradiotherapy and a complete resection appears to be technically feasible. It is recommended to apply this treatment in a research setting. - High-dose concurrent chemoradiotherapy is advised as the standard treatment for stage III non-small cell lung cancer in patients in good physical condition.

UR - http://www.scopus.com/inward/record.url?scp=57949105437&partnerID=8YFLogxK

M3 - Review article

C2 - 19192584

AN - SCOPUS:57949105437

VL - 152

SP - 2714

EP - 2717

JO - Nederlands Tijdschrift voor Geneeskunde

JF - Nederlands Tijdschrift voor Geneeskunde

SN - 0028-2162

IS - 50

ER -